HQY / HealthEquity, Inc. (BMV) - Forecast, Price Target, Estimates, Predictions

HealthEquity, Inc.
MX ˙ BMV ˙ US42226A1079
Projected Stock Price
No data available.
Projected Revenue

No data available.
Projected Earnings Per Share

1.10 ↑59.56%

Estimated quarterly earnings by March 31, 2027.

Price Target
No data available.
Stock Upgrades/Downgrades

This card shows analyst upgrades/downgrades for HealthEquity, Inc.. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.

The standard analyst ratings are generally as follows:
  • Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
  • Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
  • Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.

When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.

The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.

Why Are Analyst Ratings important?

In addition to being able to interpret financial data, stock analysts have connections within the companies they cover that give them access to information retail investors do not have.

Therefore, analyst ratings can help you find opportunities in the market. However, they are guidelines more than recommendations. This is why it’s important to look at analyst ratings over a period of time.

If analysts change their ratings frequently, you should pay close attention to the company’s fundamentals. For example, has there been a significant change to the company’s earnings growth and/or debt?

You should also pay attention to the number of analysts covering a stock over the course of a year. In general, the more analysts who cover the stock give the consensus rating more credibility, but each individual rating less overall weight.

How to Use Analyst Ratings ?

Analyst ratings are one data point for you to consider. Here are some strategies you can use to fine tune your research.

Look at more than one analyst and don’t hesitate to look at analysts that have differing views. This can help challenge any preconceived ideas you have about a stock and point out ways in which your thesis for owning or avoiding a stock may have changed.

Compare a stock’s rating with other stocks in its industry or sector. In some cases, a stock is simply superior to others in its sector. However, at other times, it could be overvalued based on investor sentiment instead of fundamentals.

How are the Fintel Analyst Ratings different?

Analyst ratings by Fintel are presented in close to real-time to stay ahead of generalized information flow. Combined with target price estimates and revenue estimates for the company you have greater accuracy despite market volatility.

Date Analyst Prior Latest
Recommendation
Action
2025-09-03 JP Morgan Overweight Overweight Maintains
2025-09-03 Jefferies Buy Buy Maintains
2025-09-03 Barrington Research Outperform Outperform Maintains
2025-09-03 RBC Capital Outperform Outperform Maintains
2025-03-19 Barrington Research Outperform Outperform Maintains
2025-03-14 Barrington Research Outperform Outperform Maintains
2025-02-26 Wells Fargo Overweight Overweight Maintains
2025-02-25 Raymond James Outperform Outperform Maintains
2024-12-10 RBC Capital Outperform Outperform Maintains
2024-12-10 JMP Securities Market Outperform Market Outperform Maintains
2024-12-04 Mizuho Outperform Initiate
2024-12-02 Barrington Research Outperform Outperform Maintains
2024-11-15 Goldman Sachs Neutral Initiate
2024-11-14 BTIG Buy Buy Maintains
2024-11-13 B of A Securities Buy Buy Maintains
2024-09-20 Barrington Research Outperform Outperform Maintains
2024-09-04 Barrington Research Outperform Outperform Maintains
2024-09-04 JMP Securities Market Outperform Market Outperform Reiterate
2024-09-04 Deutsche Bank Buy Buy Maintains
2024-09-04 RBC Capital Outperform Outperform Reiterate
2024-09-04 B of A Securities Buy Buy Maintains
2024-08-30 Barrington Research Outperform Outperform Maintains
2024-07-03 B of A Securities Buy Buy Maintains
2024-06-20 Wells Fargo Overweight Overweight Maintains
2024-06-07 Raymond James Outperform Outperform Maintains
2024-06-05 Keybanc Overweight Overweight Maintains
2024-06-04 Barrington Research Outperform Outperform Maintains
2024-06-04 Wells Fargo Overweight Overweight Maintains
2024-06-04 RBC Capital Outperform Outperform Reiterate
2024-06-04 B of A Securities Buy Buy Maintains
2024-06-04 JMP Securities Market Outperform Market Outperform Maintains
2024-06-04 Baird Outperform Outperform Maintains
2024-04-04 JMP Securities Market Outperform Initiate
2024-04-02 JP Morgan Overweight Overweight Maintains
2024-03-22 Barrington Research Outperform Outperform Maintains
2024-03-22 Keybanc Overweight Overweight Maintains
2024-03-20 BTIG Buy Buy Maintains
2024-03-20 RBC Capital Outperform Outperform Maintains
2024-03-20 B of A Securities Buy Buy Maintains
2024-02-23 Barclays Overweight Overweight Maintains
2024-02-23 RBC Capital Outperform Outperform Maintains
2023-12-13 Raymond James Outperform Outperform Maintains
2023-12-06 Wells Fargo Overweight Overweight Maintains
2023-12-04 Barrington Research Outperform Outperform Reiterate
2023-12-01 JP Morgan Overweight Overweight Maintains
2023-09-21 Baird Neutral Outperform Upgrade
2023-09-07 Deutsche Bank Buy Buy Maintains
2023-09-06 Barrington Research Outperform Outperform Reiterate
2023-09-06 RBC Capital Outperform Outperform Maintains
2023-06-07 Deutsche Bank Buy Buy Maintains
2023-06-06 RBC Capital Outperform Reiterate
2023-06-01 Barrington Research Outperform Outperform Reiterate
2023-03-24 Deutsche Bank Buy Maintains
2023-03-22 Barrington Research Outperform Reiterate
2023-03-22 RBC Capital Outperform Reiterate
2023-02-03 Wells Fargo Overweight Maintains
2023-01-24 Deutsche Bank Buy Maintains
2022-12-12 Raymond James Outperform Maintains
2022-12-07 Guggenheim Buy Maintains
2022-12-07 Wells Fargo Overweight Maintains
2022-12-05 RBC Capital Outperform Maintains
2022-10-25 Wells Fargo Overweight Maintains
2022-10-21 Goldman Sachs Sell Neutral Upgrade
2022-09-16 Keybanc Overweight Initiate
2022-09-13 Wells Fargo Overweight Maintains
2022-09-12 Raymond James Outperform Maintains
2022-09-08 Deutsche Bank Buy Maintains
2022-09-07 Baird Neutral Maintains
2022-07-12 Goldman Sachs Sell Initiate
2022-06-08 Deutsche Bank Buy Maintains
2022-06-07 SVB Leerink Outperform Maintains
2022-04-11 Wells Fargo Overweight Initiate
2022-04-07 Guggenheim Buy Initiate
2022-03-30 BTIG Neutral Buy Upgrade
2022-03-28 Jefferies Buy Maintains
2022-03-24 Deutsche Bank Buy Maintains
2022-02-24 Deutsche Bank Buy Maintains
2021-12-21 JP Morgan Overweight Maintains
2021-12-08 Deutsche Bank Buy Maintains
2021-12-07 Raymond James Strong Buy Outperform Downgrade
2021-12-07 RBC Capital Outperform Maintains
2021-12-02 Jefferies Buy Initiate
2021-09-21 Deutsche Bank Buy Maintains
2021-09-09 SVB Leerink Market Perform Outperform Upgrade
2021-07-02 Stephens & Co. Overweight Initiate
2021-06-10 Raymond James Strong Buy Maintains
2021-06-08 Cantor Fitzgerald Overweight Maintains
2021-03-22 Raymond James Strong Buy Maintains
2021-03-17 Deutsche Bank Buy Maintains
2021-03-16 SVB Leerink Market Perform Maintains
2021-02-10 Raymond James Strong Buy Maintains
2021-02-09 RBC Capital Outperform Maintains
2021-01-07 BTIG Neutral Initiate
2020-12-02 SVB Leerink Market Perform Maintains
2020-12-02 KeyBanc Overweight Sector Weight Downgrade
2020-11-23 Guggenheim Buy Neutral Downgrade
2020-10-23 RBC Capital Outperform Initiate
2020-09-09 Wells Fargo Overweight Maintains
2020-09-09 SVB Leerink Market Perform Maintains
2020-06-03 Cantor Fitzgerald Overweight Maintains
2020-04-14 Guggenheim Buy Initiate
2020-04-08 Raymond James Strong Buy Reiterate
2020-03-27 Raymond James Strong Buy Maintains
2020-03-26 SunTrust Robinson Humphrey Buy Maintains
2020-03-18 Deutsche Bank Buy Maintains
2020-03-17 KeyBanc Overweight Maintains
2020-03-17 Cantor Fitzgerald Overweight Reiterate
2020-03-17 Baird Neutral Maintains
2020-03-17 SunTrust Robinson Humphrey Buy Maintains
2020-02-20 Deutsche Bank Buy Maintains
2020-02-19 Wells Fargo Overweight Maintains
2020-02-19 KeyBanc Overweight Maintains
2020-01-08 Wells Fargo Overweight Maintains
2019-12-04 KeyBanc Overweight Maintains
2019-10-07 Goldman Sachs Neutral Initiate
2019-09-17 KeyBanc Overweight Maintains
2019-09-12 Deutsche Bank Buy Initiate
2019-09-09 Raymond James Outperform Strong Buy Upgrade
2019-09-04 Oppenheimer Outperform Maintains
2019-09-04 Wells Fargo Outperformer Maintains
2019-07-19 Bank of America Neutral Buy Upgrade
2019-06-10 Raymond James Outperform Reiterate
2019-03-19 Bank of America Neutral Neutral Maintains
2019-03-19 KeyBanc Overweight Overweight Maintains
2019-02-07 SunTrust Robinson Humphrey Hold Buy Upgrade
2018-12-18 Cantor Fitzgerald Neutral Overweight Upgrade
2018-12-07 Wells Fargo Outperform Outperform Maintains
2018-12-06 SunTrust Robinson Humphrey Buy Hold Downgrade
2018-12-06 Cantor Fitzgerald Neutral Neutral Maintains
2018-09-10 Raymond James Outperform Outperform Maintains
2018-09-06 Bank of America Buy Neutral Downgrade
2018-09-05 Cantor Fitzgerald Neutral Neutral Maintains
2018-09-05 Wells Fargo Outperform Outperform Maintains
2018-09-04 KeyBanc Overweight Overweight Maintains
2018-06-05 Baird Neutral Neutral Maintains
2018-06-05 Cantor Fitzgerald Neutral Neutral Maintains
2018-06-05 KeyBanc Overweight Overweight Maintains
2018-05-31 Cantor Fitzgerald Overweight Neutral Downgrade
2018-04-24 JP Morgan Overweight Overweight Maintains
2018-04-05 KeyBanc Overweight Overweight Maintains
2018-03-20 KeyBanc Overweight Overweight Maintains
2018-03-20 Oppenheimer Outperform Outperform Maintains
2018-03-20 Baird Neutral Neutral Maintains
2018-03-20 Chardan Capital Buy Buy Maintains
2018-02-07 Cantor Fitzgerald Overweight Overweight Maintains
2018-02-07 Baird Neutral Neutral Maintains
2018-01-24 JP Morgan Overweight Overweight Maintains
2017-03-31 Cantor Fitzgerald Overweight Initiate
2017-03-22 Chardan Capital Buy Reiterate
2017-02-07 Chardan Capital Buy Initiate
2017-01-23 KeyBanc Overweight Initiate
2016-12-13 Chardan Capital Buy Initiate
2016-09-12 Raymond James Outperform Maintains
2016-09-07 Baird Neutral Maintains
2016-06-08 SunTrust Robinson Humphrey Buy Maintains
2016-04-04 Leerink Swann Outperform Maintains
2016-03-23 Avondale Partners Market Outperform Maintains
2016-03-23 Barrington Research Outperform Maintains
2016-01-25 Leerink Swann Outperform Maintains
2015-08-17 SunTrust Robinson Humphrey Buy Maintains
2015-07-08 Leerink Swann Outperform Maintains
2015-06-09 Baird Neutral Maintains
2015-03-25 Leerink Swann Outperform Maintains
2015-03-25 JP Morgan Overweight Maintains
2015-03-06 Leerink Swann Outperform Initiate
2015-02-19 Barrington Research Outperform Initiate
2014-08-25 JP Morgan Outperform Initiate
2014-08-25 SunTrust Robinson Humphrey Overweight Initiate
2014-08-25 Raymond James Outperform Initiate
2014-08-25 Wells Fargo Outperform Initiate
2025-07-08 Raymond James Strong Buy Strong Buy Reiterate
2025-03-27 Goldman Sachs Neutral Neutral Maintains
2025-03-25 Raymond James Outperform Strong Buy Upgrade
2025-03-24 Keybanc Overweight Overweight Maintains
2025-04-11 Barrington Research Outperform Outperform Maintains
2025-04-16 Keybanc Overweight Overweight Maintains
2025-08-28 RBC Capital Outperform Outperform Maintains
2025-06-04 Goldman Sachs Neutral Neutral Maintains
2025-06-04 RBC Capital Outperform Outperform Maintains
2025-06-04 JMP Securities Market Outperform Market Outperform Maintains
2025-06-04 B of A Securities Buy Buy Maintains
2025-08-29 Barrington Research Outperform Outperform Maintains
2025-06-05 Deutsche Bank Buy Buy Maintains
2025-06-05 Barrington Research Outperform Outperform Maintains
Revenue Estimates
No data available.
Earnings Estimates

The forecasted annual earnings of HealthEquity, Inc. in 2028-03-31 is 5.40 per share.

One part of an analyst’s rating is a profit (i.e., earnings) estimate for the current quarter and/or future quarters. The measurement given is earnings per share (EPS). EPS is a metric that indicates how much a company earned as represented by one share of its stock over a specific period (typically three months).

Earnings per Share Calculation

To understand the earnings per share calculation, you must understand net income. Net income is the amount of money a company has left over after deducting appropriate expenses and taxes from its revenues).

The formula for earnings per share is net income divided by the total number of outstanding shares (i.e., available for purchase). For example:

Company A has a net income of $100 million and forty million outstanding shares. The EPS calculation is as follows:

100,000,000/40,000,000 = $2.50 per share

How to use Earnings Per Share in Stock Analysis

Earnings per share is an essential metric for you to consider when deciding to buy a stock. After all, a company with high earnings per share is productive and generates revenue in excess of its operating costs.

However, it’s not the only metric you should use. Metrics like price-to-earnings and debt-to-equity add additional perspective about a company’s health.

You should also be sure to compare a company’s EPS with a company in its sector. However, when you do, be aware that EPS is different and more important than net profit by itself. You may see a company that has a rising net profit. But if its outstanding shares are also rising, then its EPS might be flat or even edging lower.

Update Frequency: Quarterly

Date EPS Average (Quarterly) Number of Analysts (Quarterly) EPS Average (Annual) Number of Analysts (Annually)
2025-09-30 0.96 10 -- --
2025-12-31 0.92 10 -- --
2026-03-31 0.98 9 3.75 15
2026-06-30 1.12 7 -- --
2026-09-30 1.11 6 -- --
2026-12-31 1.08 6 -- --
2027-03-31 1.10 6 4.55 10
2028-01-31 -- -- 5.50 2
2028-03-31 -- -- 5.40 3
EBITDA Estimates
No data available.
EBIT Estimates
No data available.
Other Listings
US:HQY $91.48
DE:2HE €83.00
IT:1HQY €80.00
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista